SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.The new designation adds to growi ...

Key Takeaways Quest Diagnostics Inc. (DGX) is investing in advanced diagnostics to deliver and scale innovative services that improve patient care and drive growth. Acquisitions remain a key growth driver for the company. Additionally, continued strong focus on cost management further enhances the stock's appeal. Meanwhile, rising debt burden and ongoing macroeconomic volatilities raise concerns for Quest Diagnostics' operations. In the past year, this Zacks Rank #3 (Hold) stock has rallied 20.6% compared w ...

Company Overview - Quest Diagnostics is a leader in diagnostic information services, providing insights from laboratory testing to improve health outcomes [3] - The company serves one in three adult Americans and half of the physicians and hospitals in the United States, employing over 55,000 individuals [3] Upcoming Event - Jim Davis, Chairman, CEO, and President of Quest Diagnostics, will discuss the company's strategy, performance, and market trends at the Baird 2025 Global Healthcare Conference on September 10, 2025, at 10:50 a.m. Eastern Time [1] - The event will be webcast live on the company's investor relations page, with an archived version available within 24 hours after the event, remaining accessible until October 3, 2025 [2]

Core Viewpoint - Biodesix, Inc. reported strong financial results for Q2 2025, with a revenue increase of 12% year-over-year, reaching $20.0 million, and reaffirmed its full-year revenue guidance of $80-85 million [1][6]. Financial Performance - Q2 2025 revenue was $20.0 million, a 12% increase compared to Q2 2024 [1][4]. - Gross profit margin for Q2 2025 was 80%, reflecting a 150-basis point improvement from the previous year [1][11]. - Development Services revenue grew by 53% year-over-year, reaching $2.1 million [5][20]. - Lung Diagnostic Testing revenue was $17.9 million, an 8% increase from the prior year, driven by an increase in total tests delivered [5][20]. - Adjusted EBITDA loss for Q2 2025 was $7.2 million, a 29% increase in loss compared to the same period last year [11][22]. Business Highlights - The sales team expanded to an average of 74 representatives, a 21% increase from the previous year [5]. - Primary care ordering of lung diagnostic tests increased over 100% compared to pre-pilot program levels in 2024 [5]. - The company achieved an all-time high in development services business dollars under contract, totaling $12.5 million, up 54% year-over-year [5]. - Digital ordering initiatives saw a 63% increase over the prior year [5]. - The company reached patient enrollment requirements for its ALTITUDE trial in July 2025 [5]. Future Outlook - The company is positioned to achieve Adjusted EBITDA positivity in Q4 2025, supported by sales team expansion and operational effectiveness [2]. - Biodesix maintains confidence in achieving its full-year revenue guidance of $80-85 million, indicating a focus on sustainable long-term growth [2][6].

Core Viewpoint - Biodesix, Inc. will release its financial results for Q2 2025 on August 7, 2025, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Biodesix is a leading diagnostic solutions company focused on improving clinical care and outcomes for patients, particularly in lung disease [3]. - The company markets diagnostic tests such as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, which support clinical decisions for personalized care [3]. - Biodesix Development Services provide scientific, technological, and operational capabilities to biopharmaceutical and life sciences institutions, aiding in the development of diagnostic tests and therapeutics [3].

Quest Diagnostics (DGX 6.99%) reported its second-quarter 2025 results on July 22, achieving consolidated revenue of $2.76 billion (up 15.2% year over year), organic revenue growth of 5.2%, while adjusted EPS rose 11.5% year over year to $2.62. Management raised full-year revenue guidance to $10.8 billion to $10.92 billion and adjusted EPS to $9.63 to $9.83, citing sustained demand for advanced diagnostics, the integration of last year's LifeLabs acquisition, and scale-driven productivity gains. Investors s ...

Core Insights - Quest Diagnostics reported a strong second quarter for 2025, with revenues increasing by 15.2% year-over-year, driven by both organic growth and acquisitions [2][6] - The company raised its full-year guidance for 2025 based on positive performance trends and increased demand for its clinical solutions [2][3] Financial Performance - Net revenues for the second quarter reached $2.76 billion, up from $2.40 billion in 2024, marking a 15.2% increase [2][6] - Diagnostic Information Services revenues also grew by 15.7% to $2.70 billion compared to $2.33 billion in the previous year [2][6] - Adjusted diluted EPS for the quarter was $2.62, reflecting an 11.5% increase from $2.35 in 2024 [2][6] - Operating income rose to $438 million, a 23.3% increase from $355 million in the same quarter last year [2][6] Operational Metrics - Requisition volume increased by 16.3%, while organic requisition volume grew by 2.1% [2][6] - Cash provided by operations for the first half of 2025 was $858 million, up 67.1% from $514 million in 2024 [2][6] Updated Guidance - The updated guidance for full-year 2025 includes net revenues projected between $10.80 billion and $10.92 billion, an increase of 9.4% to 10.6% [3] - Reported diluted EPS is now expected to be between $8.60 and $8.80, while adjusted diluted EPS is forecasted to be between $9.63 and $9.83 [3][6]

Core Insights - Quest Diagnostics has launched a new diagnostic laboratory test for the Oropouche virus, an emerging disease prevalent in South and Central America and the Caribbean [1][2]. Company Developments - The new test will be available by prescription for clinical purposes by the end of the month, utilizing polymerase chain reaction (PCR) technology for early-stage diagnosis, with serology testing to follow later this quarter [3]. - Quest Diagnostics was awarded contracts by the U.S. Centers for Disease Control and Prevention (CDC) in September 2024 to support testing and laboratory readiness for emerging infectious diseases, including the Oropouche virus [4]. Industry Context - The Oropouche virus is transmitted by infected biting midges and some mosquito species, with a low current threat level in North America, primarily affecting travelers returning from endemic regions [2]. - The virus can cause severe neuroinvasive diseases such as meningitis and encephalitis, although most individuals recover without intervention [2].

Core Insights - Albert Anthony is a Croatian-American business author and media contributor with a focus on financial markets, having over 1,000 followers on Seeking Alpha [1] - He has a non-traditional financial background, previously working as an analyst in the IT sector for Fortune 500 companies [1] - In 2021, he launched his own equities research firm, Albert Anthony & Company, which operates remotely [1] Background and Experience - Albert Anthony grew up in the New York City area and has also lived in Austin, Texas, and Croatia, participating in various business and innovation events [1] - He has completed degrees and ongoing training from institutions like Drew University and the Corporate Finance Institute [1] - In addition to his financial commentary, he has been involved in European casting agencies and has appeared in regional media in Croatia [1] Future Endeavors - A book titled "Financial Markets: The Next Generation" is set to be launched on Amazon in 2025 [1] - A new YouTube show called "Financial Markets with Albert Anthony" is also planned for 2025, where he will provide market commentary [1]

Core Insights - Quest Diagnostics Inc. (DGX) is focusing on advanced diagnostics to enhance patient care and drive growth through strategic acquisitions and disciplined investment approaches [1][5] - The company has experienced significant stock performance, with a 27.3% increase over the past year, outperforming the industry and S&P 500 [2] - A rising debt burden is a concern, with long-term debt at $5.86 billion and cash reserves at $188 million [11] Growth Strategy - The company is targeting five major clinical areas in advanced diagnostics: advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health, all showing double-digit growth [3] - New initiatives include a self-collection option for HPV cervical cancer screening and the Haystack MRD test for early cancer recurrence risk [4] - Quest Diagnostics completed eight acquisitions in 2024, enhancing its market position, particularly in Canada and Minnesota [5][6] Operational Excellence - The company aims for 3% annual cost savings through automation and initiatives like Project Nova, which focuses on modernizing IT systems and optimizing data insights [9][10] - Collaborations with Google Cloud are intended to streamline data management and enhance customer experiences through GenAI [10] Financial Performance - The Zacks Consensus Estimate for 2025 earnings per share (EPS) is $9.70, reflecting a slight increase, with projected revenues of $10.78 billion, indicating a 9.2% growth from the previous year [13] Market Challenges - The healthcare landscape is shifting, with government payers reducing reimbursement for clinical testing services, impacting revenue potential [12] - The company faces challenges from larger insurance plans that have increased bargaining power, complicating fee negotiations [12]